# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. reiterates OPKO Health (NASDAQ:OPK) with a Buy and maintains $3 price target.
Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:OPK) with a Outperform and maintains $1.5 price ta...
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...
Labcorp acquires certain operations of Opko Health subsidiary BioReference Health. The assets Labcorp is acquiring generate abo...
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corpo...
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical l...
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in ...
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their conf...